PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



	י לנונו	JNDER THE PATENT COOPERATION TREATY (PCT)	
(51) International Patent Classification 6:		(11) International Publication Number: WO 95/13535	
G01N 31/22	A1	(43) International Publication Date: 18 May 1995 (18.05.95)	
(21) International Application Number: PCT/US94/13416 (22) International Filing Date: 14 November 1994 (14,11,94)		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 08/152,541 12 November 1993 (12.11.9	3) U	Published With international search report.	
(71) Applicant: BOEHRINGER MANNHEIM CORPO [US/US]; P.O. Box 50528, 9115 Hague Road, Indi IN 46250 (US).			
(72) Inventors: LEE, Debra, McDonald; 3654 E. Fallcreek N. Drive, Indianapolis, IN 46205 (US). BURK! William; Apartment D, 1931 Madison CL, Carnel, (US). TABB, David, Lee; 3144 W. 100 North, Indi IN 46140 (US).	3, Davi IN 460	d, 12	
(74) Agents: AMICK, Marilyn, L. et al.; Bochringer M Corporation, 9115 Hague Road, Indianapolis, II (US).	fannhei N 462:	m 0	
(54) Title: GLUCOSE CALIBRATOR AND CONTROL	MATE	RIAL FOR TEST STRIPS	
(57) Abstract			
A non-serum based calibrator and control reagent is disclosed which is useful for calibrating and validating devices such as test strips for determining glucose. The reagent composition contains water, a predetermined amount of glucose, and a dihydroxy alcohol having more than 5 carbon atoms. An especially preferred dihydroxy alcohol is dipropylene glycol. A method of making the calibrator and control reagent is also disclosed.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic	SD	Sudan
CG	Congo		of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SI	Slovenia
CI	Côte d'Ivoire	KZ	Kazakhstan	SK	Slovakia
CM	Cameroon	LI	Liechtenstein	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon				

WO 95/13535 PCT/US94/13416

-1-

GLUCOSE CALIBRATOR AND CONTROL MATERIAL FOR TEST STRIPS

BACKGROUND

The present invention relates to calibrator and

control material useful in calibrating and validating
testing devices such as test strips and dipsticks. More
particularly, the present invention relates to a nonserum based, aqueous glucose calibrator and control
material and to a method for making said calibrator and

control material.

The field of clinical chemistry and clinical analysis is concerned, inter alia, with the determination and quantification of various substances in body fluids. Many examples of the substances which are determined can be given, and these include cholesterol, urea, cations, and glucose. These examples of analytes, as well as others, are assayed in diverse body fluids such as urine and blood.

15

The monitoring of the level of glucose in blood is

20 important to the management of diabetes. The level of
glucose in the blood is controlled by the amount of
carbohydrate ingested and by insulin. Too much insulin
lowers the glucose level, and too little will result in
an abnormally high level of glucose. Both circumstances

25 lead to serious health problems for the diabetic.

WO 95/13535 PCT/US94/13416

- 2 -

Most of the glucose testing done outside of the hospital laboratory is done in non-laboratory settings such as nurses' stations, physicians' offices and at home. Testing is frequently done by measuring the amount of glucose in urine. As the level of glucose rises in the blood, it exceeds the ability of the kidney to reabsorb it, and glucose is excreted into the urine.

Although measurement of glucose in urine is useful, measurement of glucose in blood provides a more accurate reflection of the condition of the subject. Urine glucose does not accurately reflect the level of glucose in the blood since the level of glucose in urine is determined by the level of glucose in the blood and the ability of the kidney to reabsorb the glucose.

Therefore, the urine sample cannot tell the diabetic how

15

low his glucose level is.

Dry reagent test strips, sometimes referred to as dipsticks, are widely used for detecting glucose in urine and blood. These devices are characterized by their simplicity of use. In general, such test strips comprise plastic strips provided at one end thereof with an absorbent paper portion which has been impregnated with reagents such as an enzyme system and a color indicator compound which produces or changes color to form a detectable signal when the test strip is contacted with the analyte being determined. This change in color can

20

25

be measured by comparing the color formed on the strip with a standard color chart calibrated to various glucose concentrations. More recently, however, to more accurately control the level of glucose in blood,

- 5 instruments have been developed which measure the color change in a reflectance photometer and thereby produce quantitative results. Examples of reaction systems which measure glucose using reflectance measurements include oxidative reactions, such as the glucose
- oxidase/peroxidase method, and reductive reactions, such as the glucose oxidase/ferricyanide method. The latter method is described in detail in Freitag, U.S. Pat. No. 4,929,545, the content of which is herein incorporated by reference. Instruments have also been developed which determine glucose by means of electrochemical methods in which a change in current is measured. An example of this technology is the amperometric, biosensor method described in PCT Application No. PCT/US90/07374, the content of which is herein incorporated by reference.
 - It will be understood that clinical analysis of the type described herein requires that any testing system be extremely accurate. In particular, when automated systems and instruments are used, it is essential to ensure that the elements of the analysis are reliable and that the measurement taken is valid. It is for this purpose that calibrator and control reagents are used.

WO 95/13535 PCT/US94/13416

Westgard and Klee, in Textbook of Clinical Chemistry, N.W. Tietz, Ed., 1986, p. 430, define "reference material" as "a material or substance one or more properties of which are sufficiently well 5 established to be used for the calibration of an apparatus or for the verification of a measurement method." "Calibration and test material" is defined as "a reference material or solution with which the test sample is compared in order to determine the concentration of analytes or other quantities."

10

15

25

The Westgard and Klee reference defines "control material" as "a specimen, or solution, which is analyzed solely for quality control purposes and is not used for calibration purposes." This standard reference work goes on to describe some of the requisites of control materials as follows: "They need to be stable materials, available in aliquots or vials, that can be analyzed periodically over a long time. There should be little vial-to-vial variation so that differences between repeated measurements can be attributed to the analytical method alone."

The above-cited reference, at page 433, discusses how the matrix of the control material should be the same as the material being analyzed. To that end, modified human serum is discussed as one type of control material. Indeed, the art now recognizes the term "control serum"

as referring to control material based upon serum. This terminology will be used herein and is different from the term "control reagent," which, as used hereafter, refers to a control material which is not based upon, and which does not contain, serum of any type.

As has been pointed out above, one of the criteria which control, and also calibration, materials have to satisfy is stability. Control materials based upon serum, however, are inherently unstable due to the various components contained therein. Further, sera will vary from source to source, so uniformity from lot to lot cannot be guaranteed. Thus, it is sometimes desirable to have a calibrator or control material based upon a non-serum or serum-free medium.

An example of a serum-free control medium, or

"control reagent" as used herein, is described in U.S.

Pat. No. 4,729,959, issued to Ryan, which is directed to

"a stable glucose reference control." This control

contains glucose in a range of from about 40 to 500

20 mg/dl, together with fixed red blood cells, in an aqueous

suspension. The range of glucose concentrations given

are sufficient to cover just about all ranges of glucose

found in, e.g., blood.

The Ryan '959 patent points to a problem with
25 aqueous control reagents at column 1, lines 50-55.
Briefly, erythrocytes impart a degree of viscosity to

blood which is absent in water based systems. This problem was also recognized in U.S. Pat. No. 3,920,580 issued to Mast. This patent teaches that aqueous solutions had not been consistent, and that a lack of reproducibility was observed when dry reagent strips were used with such materials. Mast teaches that suitable reagents could be prepared by using an antidiffusing agent in combination with glucose and water. The antidiffusing agents taught by Mast include polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, dextran, and bovine serum albumin. Beneficial amounts are taught to be between about 3 and 35 percent of antidiffusing agent. The control solution may also include adjuvants to obtain a particular color or physical appearance, which include colored latex particles and water-insoluble lake dyes.

Maurukas, in U.S. Pat. No. 3,876,375, describes a reference control which is stable in the liquid state at temperatures ranging from -20°C to ambient room

20 temperatures. Maurukas' compositions are prepared by removing from 20 to 40% of the water from an aqueous biological material and replacing it with substantially the same concentration of an alkylene polyol containing from 2 to 5 carbon atoms. Suggested alkylene polyols are ethylene glycol, propylene glycol, butylene glycol, pentanediol and glycerol. The compositions described are

10

said to be suitable for serum analysis using sequential multichannel automated analyzers. No mention is made as to the possible suitability of the compositions with test strips for measuring glucose using whole blood samples.

Kennamer et al., in U.S. Pat. No. 5,028,542, the 5 content of which is herein incorporated by reference, describe a non-serum based, glucose measurement control reagent in which the viscosity agent polystyrene sulfonate is used.

It has now been found that a suitable glucose calibrator and control reagent can be formed without using any of the materials referred to in the prior art as required ingredients. Rather, by combining a soluble dihydroxy alcohol with a predetermined amount of glucose 15 and water, along with additional optional materials, a suitable glucose calibrator or control reagent can be made.

SUMMARY OF THE INVENTION

20 The present invention is a non-serum based glucose calibrator or control reagent which comprises a predetermined, known amount of glucose, water, and a soluble dihydroxy alcohol containing more than 5 carbon atoms. A preferred dihydroxy alcohol is dipropylene 25 glycol, and a preferred concentration for the dihydroxy alcohol is between about 20 to 30 percent by weight of

the reagent composition. It was found, quite
unexpectedly, that the composition of the present
invention is useful in calibrating and validating testing
devices such as test strips for the measurement of
glucose. Additional materials such as a buffer, a
preservative, a biocide, an ionic salt, or a surfactant,
either alone or in various additive combinations, may be
mixed with the three required components. Another aspect
of the present invention is a method for making the
calibrator or control reagent by mixing the glucose,
water, and the dihydroxy alcohol containing more than 5
carbon atoms together.

Essential to the invention are a predetermined amount of glucose, water, and the recited dihydroxy

15 alcohol. The water is used, of course, to create a reagent solution in which the other components are dissolved. By "predetermined" is meant that, prior to formulation of the actual reagent, a concentration of glucose has been selected. This concentration may vary,

20 as those skilled in the art will recognize. As has been mentioned above, the art recognized, e.g., a range of from 40 to 500 mg/dl for control material, but one may envision broader ranges, e.g., from about 10 to 700 mg/dl, when the material is to be used for calibration

The essential features of the invention, when the reagent is in the form of a solution, are the solvent (water), the predetermined amount of glucose, and the dihydroxy alcohol. The dihydroxy alcohol may be present in, e.g., a range of about 20 to about 30 percent by weight of the reagent. The weight percent of the dihydroxy alcohol will be determined by criteria such as the final reagent viscosity desired and the desired diffusion or permeability characteristics of the 10 calibrator or control with the particular testing device with which it is to be used. Of course, the particular amount of dihydroxy alcohol selected should also be one which does not adversely interfere with the determination of glucose or have a negative effect on reagent 15 stability. It is not necessary that the control material have the same viscosity as whole blood; however, it is desirable that the permeability of the material, i.e., the diffusion rate of the glucose analyte, through the reagent matrix of the test strip approximate that of 20 whole blood.

Optional additional components of the calibrator or control reagent include typical additives such as buffers, preservatives, surfactants, and ionic salts.

With respect to buffers, some preferred species are succinate, HEPES (4-[2-hydroxyethyl-1-piperazine] ethane sulfonic acid), CHES (2-[N-cyclohexylamino] ethane

sulfonic acid), MOPS (3-[N-morpholino] propane sulfonic acid), MEPS (2-[N-morpholino] ethane sulfonic acid), and CAPS (3-[cyclohexylamino-1-1-propane] sulfonic acid) buffers. Preferred preservatives or biocides include imidazolidinyl urea, available under the trade name GERMALL 115 (GAF Chemicals Corp.), methylparaben (methyl-p-hydroxybenzoate) or methanol (((2-(dihydro-5-methyl-3(2H)-oxazoylyl)-1-methylethoxy)methoxy) methoxy), available as COSAN 145 (Cosan Chemical Corp.), phenoxyethanol and gentamycin sulfate, both individually and in combination.

It may also be desirable to include a colored or colorable substance in the reagent mixture. This can be desirable because body fluid samples frequently possess a particular color as one of their properties. As the control reagent is being used to calibrate per a body fluid sample, it can be useful to calibrate against conditions as similar to the tested fluid as possible, including color.

20

25

DESCRIPTION OF PREFERRED EMBODIMENTS

Example 1

A preferred formulation of the calibrator and control reagent of the present invention was prepared having the following composition:

HEPES, Na salt

30 mM

- 11 -

HEPES, free acid	30 mM
CaCl2	130 mM
NaCl	120 mM
GERMALL 115	0.3 %
Methylparaben	0.3 %
Water	77.5 %
Dipropylene glycol	22.5 %

This reagent was adjusted with NaOH to have a final pH of 7.5. Following preparation, the reagent was divided into aliquots and spiked with predetermined amounts of glucose. Theoretical or target glucose levels selected were 10, 20, 40, 60, 80, 100, 130, 180, 300, 550 and 700 mg/dl. Each of the calibrator/control mixtures was then divided into vials, and duplicates were stored under a variety of temperature conditions.

Example 2

Each of the calibrator and control mixtures described in Example 1 was then tested for its efficacy after 1 week of storage at 25°C. As explained above, one of the most important features of a control reagent is its consistency, meaning that values obtained using it should be fairly uniform from run to run.

10

20

With this in mind, each of the control materials stored at 25°C was applied to test strips containing the glucose determination system described in PCT/US90/07374. Briefly, this publication describes the determination of glucose using an amperometric biosensor system.

Twelve replicates of each calibration/control
mixture were measured, and the mean current readings at
10 seconds, standard deviations, and coefficients of
variation were calculated. Reference glucose values for
the samples were determined using hexokinase methodology
and an HITACHI 705 (Boehringer Mannheim Corp.,
Indianapolis, IN) analyzer. The results obtained are
shown in Table 1 below.

Table 1

F 623			
HK Glucose	Mean	Std.	Coeff. of
(mg/dl)	(μA)	Dev.	Variation
11.0	1.30	0.06	4.75
41.5	3.81	0.07	1.84
63.0	5.85	0.09	1.60
85.0	7.90	0.10	1.31
106.0	9.98	0.12	1.17
137.5	13.18	0.21	1.63
191.0	18.30	0.16	0.87
316.5	30.29	0.92	3.04
573.5	52.40	2.31	4.41
711.5	64.05	3.81	5.96

These results show a level of consistency well
within that required of a calibration and control

reagent, as is indicated by the comparative standard
deviation values and coefficients of variation reported
for each set of tests.

It will be understood that the specification and

10 examples are illustrative but not limitative of the
present invention, and that other embodiments within the
spirit and scope of the invention will suggest themselves
to those skilled in the art.

10

15

25

What is claimed is:

- A calibrator or control reagent for glucose determination comprising a mixture of a predetermined amount of glucose, water, and a dihydroxy alcohol having more than 5 carbon atoms.
- The calibrator or control reagent of claim 1, wherein said dihydroxy alcohol is dipropylene glycol.
- 3. The calibrator or control reagent of claim 1, wherein said dihydroxy alcohol is present in an amount ranging from about 20 to about 30 percent by weight of said calibrator or control reagent.
 - The calibrator or control reagent of claim 1, further comprising a buffer.
- The calibrator or control reagent of claim 1, further comprising a preservative.
- The calibrator or control reagent of claim 1, further comprising an ionic salt.
- A calibrator or control reagent for glucose determination comprising a mixture of glucose, water, dipropylene glycol, a buffer, a preservative, and an ionic salt.
 - 8. A process for making a calibrator or control reagent for glucose determination comprising combining a predetermined amount of glucose, water, and a dihydroxy alcohol having more than 5 carbon atoms.

- 9. The process of claim 8, wherein said dihydroxy alcohol is dipropylene glycol.
- 10. The process of claim 8, wherein said dihydroxy alcohol is present in an amount ranging from about 20 to 5 about 30 percent by weight of said calibrator or control reagent.
- 11. The process of claim 8, further comprising combining a material selected from the group consisting of a buffer, a preservative, and an inorganic salt with said predetermined amount of glucose, water, and dihydroxy alcohol.

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

Int stional application No. PCT/US94/13416

B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S.: 436/8, 12, 13, 14, 15, 16, 18, 95 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN Search terms: dipropylene glycol, control, calibrat?, glucose, dextrose C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. US, A, 3,920,580 (MAST) 18 November 1975, see entire document. Y. JP, A, 62-412 (SHIMIZU ET AL) 06 January 1987, see entire document. Y. US, A, 5,028,542 (KENNAMER ET AL) 02 July 1991, see entire document. Y. US, A, 3,876,375 (MAURUKAS) 08 April 1975, see entire document. Y. JP, A, 3-112908 (URASHIMA ET AL) 14 May 1991, see 2,7,9,11 entire document. X. Further documents are listed in the continuation of Box C. See patent family annex. Y. Special categories of dead documents are listed in the continuation of Box C. See patent family annex. **A document which may have existed a proprior discussion of the art which is not consistented to be proprior decided to envise a minimum of the pathlecino date of another circition or other special reason (as specified). **A document which may have existed an priority decided on the continuation of decoment referring to an oral disclosure, use, exhibition or other special reason (as specified) and the pathlecino date of another circition or other special reason (as specified) and the pathlecino date of another circition or other special reason (as the citation to the document in the specification that continuation and consistent or the citation and the continuation of decoment in the continuation of the continuatio	US CL : 436/8, 12, 13, 14, 15, 16, 18, 95 According to International Patent Classification (IPC) or to both national classification and IPC				
U.S.: 436/8, 12, 13, 14, 15, 16, 18, 95 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched search terms: dipropylene glycol, control, calibrat7, glucose, dextrose C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. US, A, 3,920,580 (MAST) 18 November 1975, see entire document. Y. JP, A, 62-412 (SHIMIZU ET AL) 06 January 1987, see entire document. V. US, A, 5,028,542 (KENNAMER ET AL) 02 July 1991, see entire document. V. US, A, 3,876,375 (MAURUKAS) 08 April 1975, see entire document. Y. JP, A, 3-112908 (URASHIMA ET AL) 14 May 1991, see entire document. Z,7,9,11 X JP, A, 3-112908 (URASHIMA ET AL) 14 May 1991, see entire document. Z,7,9,11 X JP, A, 3-112908 (URASHIMA ET AL) 14 May 1991, see entire document. X document defining the person latter of the act which is accountable to the continuation of Box C. See patent family annex. Y document are first to a no and declarant, use, exhibition or other special resources the children develop cannot be considered to snowless an investore segve when the document which that the prediction or other special resources, the claimed investice cannot be considered to snowless an investore segve when the document which the third prediction contained to the considered to snowless an investore segve when the document which may then devolute on priory claims or other special resources, the claimed sweetiles cannot be considered to snowless an investore segve when the document is the store above considered to snowless an investore segve when the document is the store above considered to snowless an investore segve when the document is the store above considered to snowless and investore segve when the document is the store above considered to snowless and the store sheet provider in the store above considered to snowless and the store sheet provider in the store above considered to snowles	B. FIEL	DS SEARCHED			
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN Search terms: dipropylene glycol, control, calibrat?, glucose, dextrose C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. US, A, 3,920,580 (MAST) 18 November 1975, see entire document. JP, A, 62-412 (SHIMIZU ET AL) 06 January 1987, see entire document. V US, A, 5,028,542 (KENNAMER ET AL) 02 July 1991, see entire document. V US, A, 3,876,375 (MAURUKAS) 08 April 1975, see entire document. V JP, A, 3-112908 (URASHIMA ET AL) 14 May 1991, see 2,7,9,11 entire document. V JP, A, 3-112908 (URASHIMA ET AL) 14 May 1991, see 2,7,9,11 entire document. X Further documents are listed in the continuation of Box C. Special categories of cled documents are listed on the tortion and the continuation of Box C. To the document defining the general state of the art which is not considered to be of puricular relevance, the climal desiration and the document shick may three docties are increased or of an article and common and the document of the stream of the continuation of the stream of the stream of the continuation of the stream of the stream of the continuation of the stream of the str			l by classification symbols)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. US, A, 3,920,580 (MAST) 18 November 1975, see entire document. JP, A, 62-412 (SHIMIZU ET AL) 06 January 1987, see entire entire document. US, A, 5,028,542 (KENNAMER ET AL) 02 July 1991, see entire document. US, A, 3,876,375 (MAURUKAS) 08 April 1975, see entire document. US, A, 3,876,375 (MAURUKAS) 08 April 1975, see entire document. JP, A, 3-112908 (URASHIMA ET AL) 14 May 1991, see entire document. INTERPRESENTATION OF Purificular intermational filing date from the continuation of Box C. Special categories of clade documents in cloid to purificular intermation affining date continuation of the actual completion of the intermational filing date continuation of the intermational provides of the intermational filing date continuation of the intermational inventor and	Documentat	tion searched other than minimum documentation to the	extent that such documents are included	l in the fields searched	
Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X US, A, 3,920,580 (MAST) 18 November 1975, see entire document. Y. JP, A, 62-412 (SHIMIZU ET AL) 06 January 1987, see entire document. Y US, A, 5,028,542 (KENNAMER ET AL) 02 July 1991, see entire document. Y US, A, 3,876,375 (MAURUKAS) 08 April 1975, see entire document. Y JP, A, 3-112908 (URASHIMA ET AL) 14 May 1991, see entire document. Y JP, A, 3-112908 (URASHIMA ET AL) 14 May 1991, see entire document. X Special categories of read documents. X Special categories of read documents. T according to prefer the international filing date or priority claim) or which is clot to read the contains which may throw doubts on priority claim) or which is clot to read the contains which may throw doubts on priority claim) or other document which may throw doubts on priority claim) or other document which may throw doubts on priority claim) or other document which may throw doubts on priority claim) or other document which may throw doubts on priority claim) or other document which may throw doubts on priority claim) or other document which may throw doubts on priority claim) or other document which may throw doubts on priority claim) or other document which may throw doubts on priority claim) or other document which may throw doubts on priority claim) or other document which may throw doubts on priority claim) or other document which may throw doubts on priority claim) or other document which may throw doubts on priority claim) or other document which may throw doubts on priority claim) or other document which may throw doubts on priority claim) or other document which may throw doubts on priority claim or other document which may throw doubts on priority claim to the document which may throw doubts on priority claim to the document which may throw doubts on priority claim to the document which may throw doubts on priority claim to the document which may throw doubts on priority claim to the documen		•		, search terms used)	
US, A, 3,920,580 (MAST) 18 November 1975, see entire document. Y. JP, A, 62-412 (SHIMIZU ET AL) 06 January 1987, see entire document. Y. US, A, 5,028,542 (KENNAMER ET AL) 02 July 1991, see entire document. Y. US, A, 3,876,375 (MAURUKAS) 08 April 1975, see entire document. Y. JP, A, 3-112908 (URASHIMA ET AL) 14 May 1991, see entire document. Y. JP, A, 3-112908 (URASHIMA ET AL) 14 May 1991, see entire document. X. Special caseports of ried documents. X. Special caseports of ried documents which may show doubt on priority clinicity or which is click or smallshift the publication date of about free clinical to makinh the publication date of about free clinical to makinh the publication date of about free clinical to makinh the publication date of about free clinical to makinh the publication date of about free clinical to makinh the publication date of about free clinical to makinh the publication date of about free clinical to makinh the publication date of about free clinical to makinh the publication date of about free clinical to makinh the publication date of about free clinical to makinh the publication date of about free clinical to makinh the publication date of about free clinical to makinh the publication date of about free clinical to makinh the publication date of about free clinical to makinh the publication date of about free clinical to makinh the publication date of about free clinical to makinh the publication date of about free clinical to makinh the publication and the date about free considered to another with the publication clinical to makinh the publication and the date about the clinical to makinh the publication and the date about the clinical to makinh the publication and the date about the considered to another with the publication and the public	C. DOC	CUMENTS CONSIDERED TO BE RELEVANT			
Decided referring to a seried decourse.	Category*	Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.	
JP, A, 62-412 (SHIMIZU ET AL) 06 January 1987, see entire document. Y US, A, 5,028,542 (KENNAMER ET AL) 02 July 1991, see entire document. Y US, A, 3,876,375 (MAURUKAS) 08 April 1975, see entire document. JP, A, 3-112908 (URASHIMA ET AL) 14 May 1991, see entire document. Z,7,9,11 Extracted document are listed in the continuation of Box C. Special categories of clad documents The control of puriodar reference in the continuation of Box C. Special categories of clad documents The control of puriodar reference in the continuation of Box C. The control of puriodar reference in the continuation of Box C. The control of puriodar reference in the continuation of Box C. The control of puriodar reference in the continuation of Box C. The control of the cont			ovember 1975, see entire	1,3,5-6,8,10	
entire document. Y US, A, 5,028,542 (KENNAMER ET AL) 02 July 1991, see 2,4,7,9,11 US, A, 3,876,375 (MAURUKAS) 08 April 1975, see entire document. Y US, A, 3,876,375 (MAURUKAS) 08 April 1975, see entire 2,7,9,11 Y JP, A, 3-112908 (URASHIMA ET AL) 14 May 1991, see 2,7,9,11	Υ.:		2,4,7,9,11		
US, A, 5,028,542 (KENNAMER ET AL) 02 July 1991, see 2,4,7,9,11 entire document. US, A, 3,876,375 (MAURUKAS) 08 April 1975, see entire document. JP, A, 3-112908 (URASHIMA ET AL) 14 May 1991, see 2,7,9,11 entire document. Further documents are listed in the continuation of Box C. Special caseports of ideal documents. Further documents are listed in the continuation of Box C. See patent family annex. To document defining the general state of the art which is a consistent to be of particular reterence of the decreased published one of after the international fling date or priority clinicity or which is click to matchish the publication date of about free instead or other special reason or other special reason to when the document which may throw doubte on priority clinicity or which is click to matchish the publication date of about free instead or other special reason to when the document which may throw doubte on priority clinicity or which is click to matchish the publication date of about free instead of the special reason to the considered to provide as investive say when the document is that about the considered to provide as investive say when the document is that about the considered to provide as investive say when the document is that about the considered to provide as investive say when the document is that about the considered to provide as investive say when the document is that about the considered to provide as investive say when the document is that about the considered to provide as investive say when the document is that about the provided in the same parent family decreased of the same parent family decreased or the provided in the same parent family decreased the provided or same	X 			1-2,5,8-9	
entire document. V US, A, 3,876,375 (MAURUKAS) 08 April 1975, see entire 2,7,9,11 DP, A, 3-112908 (URASHIMA ET AL) 14 May 1991, see 2,7,9,11 The entire documents are listed in the continuation of Box C. Special consportes of clead documents. To document drings the general state of the art which is not considered to be of puricular reference of clead document which may throw doubt on priority claim(i) or which is close document which may throw doubt on priority claim(i) or which is close document which may throw doubt on priority claim(i) or which is close to enablish the pulliform certains or other state of the actual completely desired to a restrict a see and declarant, use, subhibition or other document published prior to be international filing date but later than the document which may throw doubte on priority date through the document of puricular referring to as a rend discharant, use, subhibition or other document published prior to be international filing date but later than the document which may throw doubt on the document of puricular referrings to as and discharant, use, subhibition or other document published prior to be international filing date but later than the document which may throw doubt on the document which may throw document which may thro	Y	Υ	7,11		
Date of the actual completion of the international filing date but later than the part of the mane passed family Date of the actual completion of the international search Date of the actual completion of the international search Date of the actual completion of the international search Date of the actual completion of the international search Date of the actual completion of the international search Date of the actual completion of the international search Date of the actual completion of the international search Date of the actual completion of the international search Date of the actual completion of the international search Date of the actual completion of the international search Date of the actual completion of the international search Date of the actual completion of the international search Date of the actual completion of the international search Date of the actual completion of the international search Date of the actual completion of the international search Date of the actual completion of the international search report Date of the actual completion of the international search report Date of the actual completion of the international search report	Y		2,4,7,9,11		
Extracted documents are listed in the continuation of Box C. See patent family annex. See patent family annex. See patent family annex. To a considered from the general state of the art which is not considered to be of particular reterement. See patent family annex. To a considered from the general state of the art which is not considered to be of particular reterement on the children of the state of the actual complete on the considered to a substant about the	Y		2,7,9,11		
Special casegories of cited documents: The document defining the general state of the art which is not considered to be of puritical retrieved. The document defining the general state of the art which is not considered to be of puritical retrieved. The document sphilished for or sprottly desired to the condition of the expectation of the condition of the con	Y		T AL) 14 May 1991, see	2,7,9,11	
Accurated afficials the poweral state of the art which is not consistent to be of particular relevance. The settler document published on or after the international filling data and set and power and problems the extension of the principle or decrease of particular relevance, the claimed accurate to principle or season for sequence and the principle or season to sequence the principle or season to secure or season to secu	X Further documents are listed in the continuation of Box C. See patent family annex.				
"the document submitted or or start or considered to involve an investment such that is closed to enhalshis the publication date of another crisation or other special reason (as specified). "Or document referring to an orth disclower, use, exhabition or other masses. "Pr document published prior to the international filing date but lister than the priority date claimed. Date of the actual completion of the international search Date of the actual completion of the international search DATE OF TORKS. DATE OF TORKS. DATE OF TORKS.	"A" document defining the general state of the art which is not considered date and not in conflict with the application but eited to understand the principle or theory underlying the invention				
cited to establish the publication date of supdare ristons or other special research as posterior processor accounts or special research as special or section of the control of special or special control or special or special control or special or special control or special cont	E eartier document published on or after the microanoods; rising date considered novel or cannot be considered to involve an inventive step				
"O' document referring to an oral disclosure, use, stabilitions or other measure "P' document published prior to the international filing date but later than the priority date relational Date of the actual completion of the international search Date of milling of the international search OR FED 100E	cited to establish the publication date of another citation or other special reason (as specified) document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document us				
the priority date claimed Date of the actual completion of the international search Date of mailing of the international search report OREFDIOOF	"O" document referring to an arel disclosure, use, exhibition or other combined with one or more other such documents, such combination				
08 EED 100E	the priority date claimed				
	0.8 EED 100F				

Authorized officer

Arlen Soderquist Telephone No. (703) 308-0196

D. Miza for

Facsimile No. (703) 305-3230

INTERNATIONAL SEARCH REPORT

Inte 'ional application No. PC'1/US94/13416

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. US, A, 4,729,959 (RYAN) 08 March 1988, see entire document. A 1-11

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*